3D-CT-guided Percutaneous Radiofrequency Thermocoagulation for Tumor-related Trigeminal Neuralgia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03549013|
Recruitment Status : Completed
First Posted : June 7, 2018
Last Update Posted : June 7, 2018
|Condition or disease|
|Trigeminal Neuralgia, Secondary|
|Study Type :||Observational|
|Actual Enrollment :||38 participants|
|Official Title:||The Long-Term Outcome of 3D-CT-guided Percutaneous Radiofrequency Thermocoagulation for Tumor-related Trigeminal Neuralgia: A Retrospective Study.|
|Actual Study Start Date :||April 29, 2018|
|Actual Primary Completion Date :||May 5, 2018|
|Actual Study Completion Date :||May 5, 2018|
- Cumulative recurrence-free rate [ Time Frame: The enrollment of our study began on March 1st 2007 and ended on 31st October 2017. All following-up has been finished before February 28th 2018. ]The modified Barrow Neurological Institute (BNI) pain intensity score will be used to assess pain degree. Pain relief degree will be evaluated as BNI I= no pain without medication, BNI II= occasional pain, not require medication, BNI IIIa= no pain with medication, BNI IIIb= Controlled pain with medication, BNI IV= improved pain that inadequately controlled by medication, BNI IV= persistent pain that inadequately controlled by medication. A BNI grade that increased to IV-V from I-IIIb after operation was defined as recurrence.
- Patient satisfaction [ Time Frame: From pre-operation to 1 week after operation ]Patient satisfaction is evaluated by a 5-point Likert scale, while 1 point represents very unsatisfactory and 5 points indicates very satisfactory
- Adverse events [ Time Frame: The enrollment of our study began on March 1st 2007 and ended on 31st October 2017. All following-up has been finished before February 28th 2018. ]Data regarding intra-and post=operative adverse events.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03549013
|Beijing Tiantan Hospital|
|Beijing, Beijing, China, 100050|
|Principal Investigator:||Fang Luo, M.D.||Beijing Tiantan Hospital|